chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report was received on 31 July 2014 from a health care professional. A patient (date of birth not reported) had received on an unreported date an influenza vaccine and an unspecified amount of time later developed a near anaphylactic reaction. No further information reported. Outcome unknown. Note: influenza lot number, route, site and date of administration not reported. Documents held by sender: none.
Father completed paperwork indicating client was 12 yrs of age, correct DOB 9/21/2009 given also at time of registration.  Nurse preparing vaccine noted age as 12 as indicated by father and did not calculate age using DOB.  Pfizer COVID vaccine offered to parent and accepted.  COVID and other vaccines administered.  Client returned with parent at appropriate time for second dose.  Nurse administering vaccine at that time noted age was 11 yrs. and vaccine not given and why.  Mother contacted office the following day to discuss COVID being given.  Mother informed according to current CDC guidelines, dose # 1 was valid and that second dose should be given when the client turns 12 yrs of age.  Mother also told that if CDC guidance changes she would be contacted.   Mom verbalized understanding
pt recv vax 17JAN96 & 27MAR96 pt exp mild shingles;presented to MD;f/u info indicated on 29MAR96 pt was covered w/shingles in a rt T-9 distribution & was hosp for 2 days;lab eval revealed varicella cult neg & Tzanck prep positive;pt recover
Swelling at injection sight, redness, irritation, itching, diarrhea, leg cramps, numbness, and tingling, crying.  Took to emergency room for treatment, ice-pack on arm injection sight, and Benadryl.
ADACEL & MENACTRA administered right arm 11/21/12. Patient returned on 11/23/12 with dx. cellulitis right upper arm.
Patient called on 1/02/07, to report having a rx to the Hepatitis A & B, Adult Dose vaccination she received on 12/29/07. The patient reported seeing hives appear on each arm around the vaccination area the evening of the vaccination; however, she denies any problems with the hives itching.  The vaccinations were given 12/29/07 approx. 8:45 AM. No unusual events were indicated or reported during the vaccination appointment.
food started tasting bad 4 days p/shots;one day later devel extremely sore throat; 10NOV went to acute care given ATB;devel cough on 25NOV95;taste of food has not improved & throat sitll feels strange;lost 30 lbs;
Redness, swelling, and itching rashes around injection site for about 3 days. I put topical steroid and anti-itch topical lotion on the area to relieve the itching rashes. The symptoms went away after 1 week.
No adverse event; HCP states that they administered 16 shots to patients after their expiration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP states that they administered 16 shots to patients after their expiration date) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 048L21A) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. It was unknown if patient had any relevant medical history conditions, allergy, concomitant diseases and risk factor.     In 2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. In 2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP states that they administered 16 shots to patients after their expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP states that they administered 16 shots to patients after their expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (HCP states that they administered 16 shots to patients after their expiration date).    No concomitant medication was reported.  Suspect product dosage text was reported as unknown. The intact cartons of 0.5 ml of were initially stored in the refrigerator and the thaw dates were the same as administration dates as 01-Sep-2022 ,25-Aug-2022, 04-Aug-2022, 26-Jul-2022 and 19-Jul-2022. The vial did not undergo any temperature excursions. No treatment medication was reported. This case is reported for patient 6 out of 16 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-739796 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-739796:master case
Systemic: Confusion-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Fainting / Unresponsive-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Shakiness-Medium, Additional Details: Patient passed out about 5 minutes after receiving the covid vaccine, he was sweaty, and recovered after a few minutes, we gave water and crackers
Patient admit to hospital on 6/10/22 w/ COVID pna s/p 3 Moderna doses (1/13/21, 2/10/21, and 9/8/21). Pt received treatment with remdesivir & dexamethasone.
Fine rash all over baby - itching, several hours after injection given.  Office closed.  Infant took to ER.
headache; Achy joints; This case was reported by a consumer via call center representative and described the occurrence of headache in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced headache and joint pain. On an unknown date, the outcome of the headache and joint pain were not recovered/not resolved.   It was unknown if the reporter considered the headache and joint pain to be related to Shingrix.  Additional details were provided as follows: The patient had reported the case for herself. The age at vaccination was not reported. The patient experienced headache and achy joints and asked if she take an over the counter medicine would it made the vaccine ineffective. The patient asked if she could take acetaminophen after receiving second dose. The patient was recommend to speak with her healthcare provider regarding above question and healthcare provider would determine the right treatment plan for her. The follow-up would not possible as no contact details were available.
Information has been received from a healthcare professional concerning an unknown number of unspecified patients. In November 2015, the patients were vaccinated with improperly stored M-M-R II (lot # L015281, expiry date: 30-APR-2017) and, also in November 2015, with another lot of the vaccine (lot # L024268, expiry date: 01-JUL-2017). Route and dose for both lots were not reported. It was mentioned that the vaccinations took place "since 09-NOV-2015", but since another vaccine was also involved, the exact date of vaccination is unknown. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
I received the vaccine on 01/07/2022. The next morning I woke up around 2AM I was experiencing severe pounding headache, diarrhea, muscle ache, and chills. Symptoms lasted approx. a day.
This spontaneous report was received from a healthcare professional refers to an unknown number of patients of unknown age. Since 05-APR-2016, the patients were vaccinated with an improperly stored RECOMBIVAX HB lot # L033343, 13-SEP-2017. Temperature excursion 34 Fahrenheit for 93 minutes. No adverse effects reported. This is one of the two reports received from the same reporter. Additional information has been requested.
Pt presented 8/28/21 to ED with bleeding starting 1 day prior on 8/27/21. She was 9 wks 4 days pregnant. US did not show IUP or ectopic pregnancy. Hcg level was 2550 and on exam POC were extracted from cervix with decrease in bleeding.
Alopecia; worsening condition; This is a spontaneous report from a contactable consumer (patient) via Pfizer Clinical Trials Contact Center.  A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient stated she would like to know any new findings on alopecia after Pfizer covid-19 vaccine. She had got one shot 2 months ago and has postponed second dose because of worsening condition. At the time of this report, the outcome of alopecia and condition aggravated was unknown.   No follow-up attempts are possible, no information is expected.
REDNESS, ITCHING, IRRITATION AT INJECTION SITE THAT PERSISTED FOR OVER 10 DAYS AFTER RECEIVING THE FIRST DOSE OF THE MODERNA COVID VACCINE.  SHE DESCRIBED A GENERALIZED, ODD, TINGLY FEELING THAT SHE HAD NEVER FELT BEFORE BUT DESCRIBED THE IRRITATION AS RESEMBLING A BAD BUG BITE. SIZE OF RASH, WHICH WAS NOT BLISTERING, OOZING, OR FLAKING, COVERED A SIZE ROUGHLY 3-4 TIMES THE SIZE OF HER PALM.
flu; Initial information was received on 01-Feb-2021 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case involves a patient (demographics unknown) who had flu (influenza), after received INFLUENZA VACCINE.  The patient's past vaccination(s) included influenza vaccine for prophylactic vaccination. The previous vaccinations had always made the patient not feel good for a couple of days.  The patient had no medical history, concomitant disease or risk factor.  Medical treatment(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu (influenza) about two weeks later following the administration of INFLUENZA VACCINE.  It was unknown if the patient experienced any additional symptoms/events  There were no lab data/results available.   It was not reported if the patient received any corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on the batch number for this case.
Unable to work for 1.5 days; Fever; Headache; Extreme fatigue; Pain at injection site; Sore throat; Lack of appetite; This spontaneous case was reported by an other health care professional and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat), DECREASED APPETITE (Lack of appetite), IMPAIRED WORK ABILITY (Unable to work for 1.5 days), PYREXIA (Fever) and HEADACHE (Headache) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in November 2020.    On 12-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 12-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (Sore throat), DECREASED APPETITE (Lack of appetite), PYREXIA (Fever), HEADACHE (Headache), FATIGUE (Extreme fatigue) and VACCINATION SITE PAIN (Pain at injection site). On an unknown date, the patient experienced IMPAIRED WORK ABILITY (Unable to work for 1.5 days). At the time of the report, OROPHARYNGEAL PAIN (Sore throat), DECREASED APPETITE (Lack of appetite), IMPAIRED WORK ABILITY (Unable to work for 1.5 days), PYREXIA (Fever), HEADACHE (Headache), FATIGUE (Extreme fatigue) and VACCINATION SITE PAIN (Pain at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported by the reporter.  Treatment medication was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Additional information received on 26-May-2021 and does not contain any new information
pt devel a high fever 106 approx 2 hr p/vax; pt transferred to hosp for admission;
Information has been received from an office manager concerning a female who on 06-AUG-2008 was vaccinated with a dose of VAQTA. On 06-AUG-2008, the office manager reported that the patient was scheduled to receive the third dose of GARDASIL. However, after evaluating the office vaccine count, the patient may have received VAQTA instead of GARDSIL. No adverse effects have been reported. A product quality complaints was not involved. Additional information has been requested.
serious chest pressure pain; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (serious chest pressure pain) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included CLOPIDOGREL BISULFATE (PLAVIX) and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Mar-2021, the patient experienced CHEST PAIN (serious chest pressure pain). On 09-Mar-2021, CHEST PAIN (serious chest pressure pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient has stents. No treatment was reported.  The second night after the first dose around 7p patient had serious chest pressure pain. This lasted for 2-3 nights. He did inform his doctor.
Starting before receiving the vaccine, I had some issues with dry eyes but was using eye drops without relief. I tried REFRESH, SYSTANE, THERATEARS and BIOTRUE. When I received the vaccine, I believe  it continued to worsen after receiving the vaccine. I am unsure if it's related to having COVID-19 back in June of this year since I started having the dry eye symptoms in late summer after having COVID-19. When I went to the doctor, she did a few tests for glaucoma for follow up. I was prescribed KLARITY-C but it was too expensive and I am going to see if there is an alternative covered by insurance. The main reason I had gone to the doctor was because I was concerned that I had something more going on than just dry eyes because my eyes felt very tired and sore. They felt so fatigued that I felt I needed to close my eyes and rest. Also, they were bloodshot as well. Doctor did not see anything more than dry eye.
Recieved H1N1 vaccine.  10 minutes later, had subjective shortness of breath and eye puffiness.
A 43 year old female experienced loss of muscle function in neck, arms, and legs and difficulty breathing after receiving RabAvert, dose unknown, for prophylactic rabies treatment from 12/02 to 1/03. The patient's medical history includes diabetes for which she is taking Glucophage and Glucotrol. The patient was bitten by a skunk on 12/15/02 and began treatment with RabAvert at that time. After the first injection, she experienced, loss of muscle function in neck, arms and legs, and difficulty breathing. She reports that symptoms worsened with each injection in the series. The events were reported the the state health department, however, she reports that she was instructed to continue the series through completion. The patient's physician was also made aware of the symptoms and hesitated to complete the course, but did so anyway. Her physician has told her that she has, central and peripheral nervous system damage. She also reported having experienced inflammation in both eyes and has had to seek treatment from an ophthamologist. Follow up phone call to patient on 6/3/03: Patient reports continuing to have decreased muscle function in neck, arms, and legs. She has tremors on the right side of her body that occur while using that particular part of her body. She states that as she becomes tired, the tremors shift to the left side of her body. Additionally, she is now seeing an ophthamologist for bilateral uveitis. (OMIC)
HIVES/RASH on BODY.  START ON UPPER ARMS AND TORSO AND SPREAD TO THE LOWER EXTREMETIES.  PT WAS GIVEN BENADRYL, CALAMINE LOTION, OATMEAL BATH and HYDROCORTISONE CREAM.  RASH CLEARED UP 2-3 Days after starting.  Was very itchy and uncomfortable
Chills; Joint pain; This is a spontaneous report from a contactable other health professional. A 55-year-old male patient received the 2nd dose of bnt162b2 (BNT162B2, Manufacturer Pfizer-BioNTech), intramuscular in left arm, in Dec2020, at single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Previously the patient received the 1st dose of bnt162b2 (BNT162B2, Manufacturer Pfizer-BioNTech) for COVID-19 immunisation. The patient experienced chills and joint pain both in Jan2021, 6 days after vaccination, with outcome of recovered after several hours.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pregnant; This spontaneous prospective pregnancy case was reported by a health care professional and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a 31-year-old female patient (gravida 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     The patient's past medical history included Miscarriage on 15-May-2020. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 13-Jan-2021 at 10:20 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 10-Aug-2020 and the estimated date of delivery was 17-May-2021. On 13-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-second week of the pregnancy.  On 13-Jan-2021, EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Sep-2020, Pregnancy test: positive (Positive) Positive. On an unknown date, Ultrasound scan: normal (normal) normal for both.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication was not reported.  This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. No information regarding the patient's medical history or concurrent conditions was provided. On unknown date, the patients were vaccinated with multiple doses of VAQTA injection lot # N005274 and expiry date: 03-APR-2018, lot # N005796 and expiry date: 26-MAY-2018 (exact dose and route of administration were not reported). There were no concomitant therapies reported. The administered doses of the vaccine were exposed to a temperature between 47 degrees Fahrenheit to 77 degrees Fahrenheit on an unspecified date, for a time frame of 134 hours. A digital data logger was involved. There were no previous temperature excursions recorded. No adverse experiences were reported. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1708USA010162: US-009507513-1708USA010561.
After receiving the vaccine on 1/19/21. I noticed I lost my sense of smell on 1/21/21. I was sent to take the COVID-19 test on 1/21/21 in which I tested positive.
Initial report received from a health care professional on 02 November 2010. A female patient (age not specified) received an injection (route and site not provided) in 2006 of MENACTRA, lot number not reported. On an unspecified date one and a half weeks ago, the patient died from group C meningococcal disease. No further information was available. Documents held by sender: None.
11SEP95 approx 9PM pt became unresponsive, cold and clammy, limp which lasted for 2-3mins or so;mom reports color returned slowly, became responsive;cont to run low grade fever through the next day, treated w/APAP drops
Chills, body aches, nausea, headache, tired beginning 7 hours after the vaccination and last 30 hours.  I did not seek treatment.  After 30 hours the symptoms had largely subsided other than a minor headache.  Within 48 hours the headache was also gone.
I went back to work, but started feeling a little sluggish around 2pm. By 5:30pm, I had a fever. It went up to 101 and I had chills throughout the night. I was extremely nauseous and then started vomiting. Afterwards, I went back to bed. I continued to monitor my temperature and drinking fluids. I felt depleted and I was extremely achy. I had a headache, but not a migraine like the first time. It lasted for about 48 hours just like the first time. By Sunday evening, my symptoms started to go away. I didn't eat much, though. I was able to go to work the next day.  Did not seek treatment this time.
Information has been received from a medical assistant concerning multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical histories and concomitant therapies were not provided. On unknown dates, the patients were vaccinated with improperly stored PROQUAD (dose and route were unknown; lot # M004894 with expiration dates 26-JUL-2017(recombinant human albumin (rHA)) and lot # L039268 with expiration date 05-APR-2017). The vaccines were exposed under temperature of 5.5 degrees Fahrenheit for 1 hour. The previous temperature excursion was 25.6 degrees Fahrenheit for 13 hours cumulative. Data Logger was involved. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Within 5 minutes after administering flu vaccine pt arm became red & hot to the touch, comparable to a baseball size area. No SOB, no other side effects reported.
Cerebral infarction, unspecified; unspecified convulsions; facial weakness.
a few minutes after receiving the injection, the patient complained of a racing heartbeat, "funny feeling" in her head, and started to develop a red rash across her chest, neck and face. she said she had no trouble breathing, but her heart was pounding hard. I advised her to remain seated and tell me if she started having any trouble breathing or feeling her throat swell.  When her racing heart and redness did not go away in about 10 minutes, I advised that I call an ambulance for her, which she and her husband agreed to. I then called 911 and the paramedics came to attend to her after about 15 minutes.  They found her blood pressure to be highly elevated and advised she let them take her to the emergency room. She and her husband agreed, and they left for the hospital in the ambulance.